Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Pivekimab Sunirine · Decnupaz, IMGN-632

Antibody-drug conjugate · Kills target cells, directed at CD123 (IL3RA) · developed by Abbvie

Approved FDA, May 2026

ABBV Developer

1 Registered trials

What is Pivekimab Sunirine?

Pivekimab sunirine is a humanized anti-CD123 antibody-drug conjugate that delivers a DNA-alkylating payload (FGN849) to CD123-expressing cells. Upon internalization, the payload causes DNA damage, apoptosis, and cell death.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Decnupaz, IMGN-632
Drug type: Antibody-drug conjugate
Targets: CD123 (IL3RA)
Mechanism: Kills target cells, directed at CD123 (IL3RA)
Pathways: DNA alkylation, apoptosis
Therapy area: Oncology
Developer: Abbvie Inc (ABBV)
FDA status: Approved as Decnupaz (May 27, 2026), BLA761460 · FDA label
UNII: L15LO3W1XX

✅ FDA-approved uses

Blastic plasmacytoid dendritic cell neoplasm

From the indications section of the FDA label (version of May 27, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07581002	Phase 2/3	Acute Myeloid Leukemia	Recruiting	ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia

Other drugs acting on IL3RA

Mipletamig Phase 1

More from Abbvie

Adalimumab FDA approved Atogepant FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1 ABBV-438 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Pivekimab Sunirine

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z